We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Pushes Higher Standards for Critical-Dose Drugs
Advisory Committee Pushes Higher Standards for Critical-Dose Drugs
August 2, 2011
An FDA advisory committee recommends tighter bioequivalence standards for generic versions of narrow therapeutic index (NTI) drugs — sometimes called critical dose drugs — as small differences in dosing can lead to dangerous side effects.